LeadArtis leads the cancer immunotherapy with bispecific costimulatory antibodies (IBIMAB) project

02-09-2016

LeadArtis is proud to announce its participation as coordinator of the IBIMAB project (Cancer immunotherapy with bispecific costimulatory antibodies) funded by the Spanish Ministry of Economy and Competitiveness (MINECO) under the RETOS 2016 Collaboration program. IBIMAB counts with collaborators such as the internationally regarded research institutions: Centro de Investigación Médica Aplicada-CIMA (Pamplona, Spain), Hospital Universitario Puerta de Hierro-HUPH (Madrid, Spain) and Instituto de investigaciones biomédicas Alberto Sols-IIBm-CSIC (Madrid, Spain). The MINECO’s funding demonstrates the support of LeadArtis technology and main objectives.

Some of the most effective cancer immunotherapy strategies are based on the modulation of molecular interactions dubbed immune check-points using monoclonal antibodies (mAbs). LeadArtis generates bispecific hexavalent trimerbodies (BHTs) exploiting the expression of two cell surface antigens, one a costimulatory molecule on the T cells and the other a tumor-associated antigen (TAA) on the tumor cells. The anti-TAA specificity allows efficient location of the BHT into the tumor deposits, providing a more efficient interaction with the costimulatory antigen expressed on the surface of tumor infiltrating T lymphocytes. Our company focuses on two clinically validated mechanisms of action synergistic when combining individual mAbs (IgG type). LeadArtis will use its proprietary trimerbody® technology to generate a fully human bispecific hexavalent antibody as candidate for development.

LeadArtis is the leading company aiming to bring to the market cancer immunotherapeutic trimerbodies. Despite recent advances in the field, most of the current initiatives are early stage and exploratory. Currently, most of current immune-checkpoint blockers in development are conventional monoclonal antibodies (mAbs); comparatively, recombinant antibody technologies are strongly positioned and shortly will become preferred for clinically validated mechanisms of action. The trimerbody added value is multivalence and multispecificity, small size & ease of manufacturing to generate more effective compounds. 

Latest News

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...

LeadArtis participates in the third Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting
09-12-2016

The third IACT review meeting took place on October 25-26, 2016 in Frankfurt, Germany. LeadArtis...

Leadartis to present at BioSpain 2016 in Bilbao
25-08-2016

Leadartis will participate in BioSpain 2016 to be held...